The relationship between metabolic hormone levels and the prevalence of hypertension in people under 45 years of age

Among the various factors potentially involved in the pathogenesis of cardiovascular diseases, arterial hypertension (HTN), in the structure of which the proportion of young people increases, is still the most common risk factor for the development of serious cardiovascular complications. The development of structural and functional disorders associated with HTN is accompanied by an increase or decrease in markers of metabolic disorders. Objective. Тo study the prevalence of HTN in young people of working age and childbearing age, depending on the levels of metabolic hormones. Design and methods. The study included 1,340 people from the Novosibirsk population sample aged 25–44 years. HTN was diagnosed in case of the average systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg. The levels of amylin, C-peptide, ghrelin, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), glucagon, insulin, pancreatic polypeptide (PP), and peptide YY (PYY) were determined by multiplex analysis. Results. In the quartile with the highest values of amylin, C-peptide, GIP, GLP-1 and PP, the prevalence of HTN is significantly higher compared to Q1. In the group of HTN patients, the levels of amylin, C-peptide, ghrelin, GIP, GLP-1, insulin and PP were 2,4 (p < 0,0001), 1,4 (p < 0,0001), 1,3 (p = 0,001), 1,3 (p = 0,003), 1,6 (p = 0,001), 1,2 (p = 0,002) and 1,4 (p = 0,006) times higher, respectively, in comparison with persons without HTN. Conclusions. The prevalence of HTN is associated with high values of amylin, ghrelin, glucagon, insulin and C-peptide. The chance of HTN increases starting from the second quartile of amylin and increases with each quartile.

1. Lewington S, Clarke R, Qizilbash N, Peto R, CollinsR. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–1913. doi:10.1016/s0140-6736(02)11911-8

2. Klimov AV, Denisov EN, Ivanova OV. Arterial hypertension and its prevalence among the population. Molodoj Uchenyj. 2018;50(236):86–90. In Russian

3. Nagaeva GA, Mamutov RSh. Arterial hypertension as a risk factor of ischemic heart disease destabilization (fragment of Racsmi-Uz study). Arterial’naya Gipertenziya = Arterial Hypertension. 2018;24(1):48–56. In Russian

4. Volpe M, Camm J, Coca A, UngerT.The cardiovascular continuum refined: a hypothesis. Blood Press. 2010;19(5):273–277. doi:10.3109/08037051.2010.481072

5. Turgunova L, Koichubekov B, Turmuhambetova A, Sorokina M, Laryushina YE, Korshukov I et al. Biochemical markers of hypertension, prehypertension. Ann Cardiol Angeiol (Paris). 2018;67(3):161–166. doi:10.1016/j.ancard.2018.04.023

6. Novials A, Rodriguez-Mañas L, Chico A, El Assar M, Casas S, GomisR.Amylin and hypertension: association of an amylin-G132A gene mutation and hypertension in humans and amylin-induced endothelium dysfunction in rats. J Clin Endocrinol Metab. 2007;92(4):1446–1450. doi:10.1210/jc.2006-1980

7. Clinical guidelines 2020. Russ J Cardiol. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786. In Russian

8. Ludvik B, Kautzky-Willer A, Prager R, Thomaseth K, PaciniG.Amylin: history and overview. Diabet Med. 1997;14(2): S9–S13. doi:10.1002/(sici)1096-9136(199706)14:2+3.3.co;2–4

9. Höppener JW, Lips CJ. Role of islet amyloid in type 2 diabetes mellitus. Int J Biochem Cell Biol. 2006;38(5–6):726–736. doi:10.1016/j.biocel.2005.12.009

10. Gong W, Liu ZH, Zeng CH, Peng A, Chen HP, Zhou H et al. Amylin deposition in the kidney of patients with diabetic nephropathy. Kidney Int. 2007;72(2):213–218. doi:10.1038/sj.ki.5002305

11. Haynes JM, Hodgson WC, Cooper ME. Rat amylin mediates a pressor response in the anaesthetised rat: implications for the association between hypertension and diabetes mellitus. Diabetologia. 1997;40(3):256–261. doi:10.1007/s001250050672

12. Ikeda T, Iwata K, OchiH.Effect of insulin, proinsulin, and amylin on renin release from perfused rat kidney. Metabolism. 2001;50(7):763–766. doi:10.1053/meta.2001.24200

13. Kailasam MT, Parmer RJ, Tyrell EA, Henry RR, O’Connor DT. Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk. J Hypertens. 2000;18(11):1611–1620. doi:10.1097/00004872-200018110-00012

14. Tokudome T, KangawaK.Physiological significance of ghrelin in the cardiovascular system. Proc Jpn Acad Ser B Phys Biol Sci. 2019;95(8):459–467. doi:10.2183/pjab.95.032

15. Gruzdeva OV, Borodkina DA, Belik EV, Akbasheva OE, Palicheva EI, Barbarash OL. Ghrelin physiology and pathophysiology: focus on the cardiovascular system. Kardiologiia. 2019;59(3):60–67. In Russian

16. Iglesias MJ, Piñeiro R, Blanco M, Gallego R, Diéguez C, Gualillo O et al. Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes. Cardiovasc Res. 2004;62(3):481–488. doi:10.1016/j.cardiores.2004.01.024

17. Iantorno M, Chen H, Kim JA, Tesauro M, Lauro D, Cardillo C et al. Ghrelin has novel vascular actions that mimic PI 3kinase-dependent actions of insulin to stimulate production of NO from endothelial cells. Am J Physiol Endocrinol Metab. 2007;292(3): E756–E764. doi:10.1152/ajpendo.00570.2006

18. Virdis A, Duranti E, Colucci R, Ippolito C, Tirotta E, Lorenzini G et al. Ghrelin restores nitric oxide availability in resistance circulation of essential hypertensive patients: role of NAD(P)H oxidase. Eur HeartJ. 2015;36(43):3023–3030. doi:10.1093/eurheartj/ehv365

19. Tesauro M, Schinzari F, Iantorno M, Rizza S, Melina D, Lauro D et al. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation. 2005;112(19):2986–2992. doi:10.1161/CIRCULATIONAHA.105.553883

20. Tesauro M, Schinzari F, Rovella V, Di Daniele N, Lauro D, Mores N et al. Ghrelin restores the endothelin 1/ nitric oxide balance in patients with obesity-related metabolic syndrome. Hypertension. 2009;54(5):995–1000. doi:10.1161/HYPERTENSIONAHA.109.137729

21. Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018;34(5):575–584. doi:10.1016/j.cjca.2017.12.005

22. Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature. 2001;414(6865):799–806. doi:10.1038/414799a

23. Wang F, Han L, HuD.Fasting insulin, insulin resistance and risk of hypertension in the general population: a metaanalysis. Clinica Chimica Acta. 2017;464:57–63. doi:10.1016/j.cca.2016.11.009

24. Sasaki N, Ozono R, Higashi Y, Maeda R, KiharaY.Association of insulin resistance, plasma glucose level, and serum insulin level with hypertension in a population with different stages of impaired glucose metabolism. J Am Heart Assoc. 2020;9(7):e015546. doi:10.1161/JAHA.119.015546